BPG is committed to discovery and dissemination of knowledge
Observational Study
Copyright: ©Author(s) 2026.
World J Gastroenterol. Sep 7, 2026; 32(33): 118185
Published online Sep 7, 2026. doi: 10.3748/wjg.118185
Table 1 Clinical characteristics of the study participants
CharacteristicsHealthy control (n = 47)BGD (n = 57)GC (n = 42)CRC (n = 63)
Age (median, range)48.0 (36.5-61.0)55.0 (44.0-65.0)58.5 (49.5-65.8)a63.0 (55.0-68.0)a
Gender (female/male)28/1927/3014/28a25/38
TNM stage
I + II--1430
III + IV--2833
CEA (ng/mL)1.16 (0.92-1.64)1.85 (1.30-2.90)2.49 (1.42-7.82)a5.04 (2.60-11.80)a
CA199 (U/mL)2.04 (0.81-6.31)12.11 (7.73-18.47)14.28 (8.97-24.65)a14.64 (6.48-99.55)a
Creatinine (μmol/L)4314 (2647-8531)9611 (5299-14520)6672 (3691-11540)a6042 (3257-12250)a
DiAcSpm (μmol/g· Cre)0.58 (0.47-0.79)0.56 (0.41-0.85)0.82 (0.61-1.25)a0.83 (0.56-1.35)a
Table 2 The relationship between urinary N1, N12-diacetylspermine and clinical features in patients with gastric cancer and those with colorectal cancer, n (%)
Clinical featuresGC
CRC
Low (n = 21)1
High (n = 21)1
P value
Low (n = 32)1
High (n = 31)1
P value
Age0.756-0.799
≤ 6013 (61.9)11 (52.4)12 (37.5)13 (41.9)
> 608 (38.1)10 (47.6)20 (62.5)18 (58.1)
Gender0.744-0.074
Male15 (71.4)13 (61.9)23 (71.9)15 (48.4)
Female6 (28.6)8 (38.1)9 (28.1)16 (51.6)
CEA (ng/mL)1.000-0.133
≤ 513 (61.9)13 (61.9)19 (59.4)12 (38.7)
> 58 (38.1)8 (38.1)13 (40.6)19 (61.3)
CA199 (U/mL)0.663-0.788
≤ 4317 (81.0)19 (90.5)23 (71.9)21 (67.7)
> 434 (19.0)2 (9.5)9 (28.1)10 (32.3)
TNM stage0.326-0.453
I + II9 (42.9)5 (23.8)17 (53.1)13 (41.9)
III + IV12 (57.1)16 (76.2)15 (46.9)18 (58.1)
Lymph node metastasis0.505-0.617
Yes13 (61.9)16 (76.2)15 (46.9)17 (54.8)
No8 (38.1)5 (23.8)17 (53.1)14 (45.2)
Distant metastasis0.028-0.064
Yes5 (23.8)13 (61.9)7 (21.9)14 (45.2)
No16 (76.2)8 (38.1)25 (78.1)17 (54.8)
Differentiation degrees0.136-0.185
Well2 (9.5)1 (4.8)4 (12.5)2 (6.5)
Moderate8 (38.1)3 (14.3)25 (78.1)21 (67.7)
Poor11 (52.4)17 (80.9)3 (9.4) 8 (25.8)


Write to the Help Desk